» Articles » PMID: 37962812

Microbiota-Gut-Brain Axis and Antidepressant Treatment

Overview
Publisher Springer
Specialty Psychology
Date 2023 Nov 14
PMID 37962812
Authors
Affiliations
Soon will be listed here.
Abstract

In the treatment of depressive disorders, conventional antidepressant therapy has been the mainstay of clinical management, along with well-established nonpharmacological interventions such as various kinds of psychotherapy. Over the last 2 decades, there has been considerable interest in the role of the gastrointestinal system and its microbiota on brain function, behavior, and mental health. Components of what is referred to as the microbiota-gut-brain axis have been uncovered, and further research has elicited functional capabilities such as "gut-brain modules." Some studies have found associations with compositional alterations of gut microbiota in patients with depressive disorders and individuals experiencing symptoms of depression. Regarding the pathogenesis and neurobiology of depression itself, there appears to be a multifactorial contribution, in addition to the theories involving deficits in catecholaminergic and monoamine neurotransmission. Interestingly, there is evidence to suggest that antidepressants may play a role in modulating the gut microbiota, thereby possibly having an impact on the microbiota-gut-brain axis in this manner. The development of prebiotics, probiotics, and synbiotics has led to studies investigating not only their impact on the microbiota but also their therapeutic value in mental health. These psychobiotics have the potential to be used as therapeutic adjuncts in the treatment of depression. Regarding future directions, and in an attempt to further understand the role of the microbiota-gut-brain axis in depression, more studies such as those involving fecal microbiota transplantation will be required. In addition to recent findings, it is also suggested that more research will have to be undertaken to elicit whether specific strains of gut organisms are linked to depression. In terms of further investigation of the therapeutic potential of prebiotics, probiotics, and synbiotics as adjuncts to antidepressant treatment, we also expect there to be more research targeting specific microorganisms, as well as a strong focus on the effects of specific prebiotic fibers from an individualized (personalized) point of view.

Citing Articles

Ghrelin, Neuroinflammation, Oxidative Stress, and Mood Disorders: What Are the Connections?.

Mingardi J, Meanti R, Paoli C, Cifani C, Torsello A, Popoli M Curr Neuropharmacol. 2024; 23(2):172-186.

PMID: 39041263 PMC: 11793048. DOI: 10.2174/1570159X22999240722095039.

References
1.
Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S . Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology. 2017; 79:40-48. DOI: 10.1016/j.psyneuen.2017.02.014. View

2.
Alcock J, Maley C, Aktipis C . Is eating behavior manipulated by the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms. Bioessays. 2014; 36(10):940-9. PMC: 4270213. DOI: 10.1002/bies.201400071. View

3.
Allen A, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G . Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J Affect Disord. 2015; 186:306-11. DOI: 10.1016/j.jad.2015.06.033. View

4.
Allen A, Hutch W, Borre Y, Kennedy P, Temko A, Boylan G . Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016; 6(11):e939. PMC: 5314114. DOI: 10.1038/tp.2016.191. View

5.
Alli S, Gorbovskaya I, Liu J, Kolla N, Brown L, Muller D . The Gut Microbiome in Depression and Potential Benefit of Prebiotics, Probiotics and Synbiotics: A Systematic Review of Clinical Trials and Observational Studies. Int J Mol Sci. 2022; 23(9). PMC: 9101152. DOI: 10.3390/ijms23094494. View